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Altered Composition of Urinary Heparan Sulfate in
Patients with COPD
CHRIS H. van de LEST, ELLY M. VERSTEEG, JACQUES H. VEERKAMP, JO H. BERDEN,
JACOB van den BORN, LEO HEUNKS, JAN-WILLEM J. LAMMERS, CEES L. van HERWAARDEN,
P. N. RICHARD DEKHUIJZEN, and TOIN H. van KUPPEVELT
Departments of Biochemistry, Nephrology, and Pulmonary Diseases, University of Nijmegen, Nijmegen, the Netherlands
In patients with emphysema the integrity of the extracellular matrix (connective tissue skeleton) is
compromised. Inthis study we analyzed glycosaminoglycans, which are main constituents of this matrix,
in urines from patients with chronic obstructive pulmonary disease (COPO)/emphysema. Glycosami-
noglycans (GAGs) were purified by anion exchange chromatography and quantified using the 1,9-di-
methylmethylene blue assay. Heparan sulfate (HS) was assayed using three different chemical methods:
digestion with heparitinase or with nitrous acid and by use of an adapted 1,9-dimethylmethylene blue
assay. A specific epitope on the HSmolecule, defined by the monoclonal antibody IM403, was deter-
mined using an inhibition enzyme immunoassay. In patients with COPOtotal urinary glycosaminogly-
can and HScontent were not altered. The IM403 epitope of HS, however, was greatly decreased in
patients (0.6 versus 4.1 units/mg creatinine for control subjects, p < 0.0001). A similar pattern was
observed when patients with bronchial carcinoma with and without emphysema were compared (0.4
versus 2.4 units/mg creatinine respectively, p <0.0005). Patients with sarcoidosis did not show a de-
creased epitope content. These results indicate a structural change or an altered processing of the HS
molecule in patients with emphysema. Taking into consideration the importance of HSfor the stability
of the alveolar extracellular matrix, this change may be associated with the pathogenesis of emphy-
sema. van de lest CH,Versteeg EM,Veerkamp JH, Berclen JH, van den Born J, Heunks l, Lammers
J-WJ, van Herwaarden Cl, DekhulJzen PNR, van Kuppevelt TH. Altered composition of urinary
heparan sulfate In patients with COPD. AM J RESPIRCRIT CARE MED 1996;154:952-8.
Airspace enlargement, destruction of alveoli,and loss of elasticity
are the hallmarks of pulmonary emphysema. A loss of the in-
tegrity of the extracellular matrix is probably underlying the dis-
ease. The vast majority of research has focused on elastin. Break-
down of elastin, however, has not been unequivocally demon-
strated in human emphysematous lung tissue (I), nor is there con-
sensus about an increase in elastin-derived peptides in serum or
urine of patients. Elevated levelsof elastin-derived peptides have
(2,3), and have not (4-6) been observed. In laboratory animals,
emphysema can be induced with and without destruction of elas-
tin (1).
Other alveolar extracellular matrix molecules like collagens,
proteoglycans, laminin, and fibronectin may also be of impor-
tance in the pathogenesis of emphysema. Proteoglycans deserve
special attention because they playa key role in the integrity of
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the alveolar wall. They are involved in the fibrillogenesis and me-
chanical characteristics of elastin and collagen (7-9), they bind
and modulate growth factors and cytokines (10), and they are
powerful inhibitors of proteases, including human leukocyte elas-
tase (11-13).
Proteoglycans are macromolecules consisting of a core pro-
tein to which negatively charged glycosaminoglycans (GAGs) are
attached. GAGs are a class of long unbranched polysaccharides,
consisting of repeating disaccharides of which one is an amino
sugar residue and the other an uronic acid residue. In the alveo-
lar wall, different types of GAGs are present (14, 15), including
heparan sulfate (HS) which is located in basement membranes
and on cell surfaces. Alterations in lung GAGs have been de-
scribed in experimental as well as human emphysema (16-21).
The results of these studies, however, are contradictory, likely
due to differences in experimental setup. In human lung, for in-
stance, an increase (16) and a decrease (17) in the percentage of
hyaluronic acid have been found; also in human lung an increase
(18) and no increase (19) in the glucosamine/galactosamine ratio
has been demonstrated.
In this study wehave analyzed the urinary excretion of GAGs
from patients with chronic obstructive pulmonary disease(COPD)
emphysema, with special emphasis on HS. For comparison, we
also studied patients with bronchial carcinoma with and with-
out emphysema, and patients with sarcoidosis. It was found that
the presence of a specific epitope of HS is considerably reduced
in urine of emphysematous patients, despite an unchanged total
HS content.
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TABLE 1
PHYSIOLOGIC DATA OF PATIENTS WITH COPD
FEVl FEV]
Patient Age (yr), BMI TLC RV (% pred) (% pred) Keo Pa02 Pae02 Pack-
Code 5ex (kg/m2) (% pred) (% pred) before 5 after 5 (% pred) (kPa) (kPa) years
JG 51, M 23.3 102 97.5 35 42 11 7.09 4 21
BR 63, M 19.6 111 135 43 49 54 NO NO 30
0 71,M 24.7 138 211 31 31 54 NO NO 20
H5 71, F 24.6 104 67 45 55 31 12.1 4.6 5
JI 65, M 23.4 104 135 23 23 41 9.5 4.7 40
V 82, M 29.6 132 177 46 54 69 6.8 6.5 40
HX 56, F 24.9 125 171 19 21 20 8.1 5.9 40
JA 57, F 24.7 94 136 28 27 50 7.8 8.1 30
JB 70, M 18.1 106 102 30 32 53 7.9 5.7 0
JH 60, M 20.5 110 196 11 14 28 8.7 6.2 30
JD 62, M 29 121 216 26 24 67 14.2 4.3 35
HZ 50, M 20.1 110 224 31 37 58 11 4.6 30
H 65, M 28.7 107 110 41 46 40 9.2 5.1 45
HU 74, M 20.9 140 174 31 33 38 11.9 4.9 20
JE 67, M 21.3 117 139 43 43 29 10.3 4.9 35
HP 70, M 22.9 113 152 21 21 49 9.7 4.9 13
HV 71, M 27.4 109 153 24 24 73 8.4 6.3 12
W 61, M 17.4 117 198 19 20 21 7.8 6.2 40
HR 79, M 24.7 94 96 55 57 61 11.1 4.9 10
HT 60, F 18 116 159 26 33 35 8.9 5.0 25
Definition of abbreviations: BMI ; body mass index (welqht/lenqtb '): TLC ; total lung capacity; RV; residual volume; FEV, ; forced
expiratory volume in one second; S; salbutamol; kco> difusion capacity for carbon monoxide corrected for alveolar volume; % pred ;
percentage of the predicted value; ND; not determined.
METHODS
Patients and Control Subjects
Three groups of patients and control subjects were studied: Group 1,
patients with COPD and matched control subjects; Group 2, patients
with bronchial carcinoma with and without emphysema; and Group 3,
patients with sarcoidosis and matched control subjects.
Physiologic data for individual patients are given in Tables 1-3. In
all groups subjects with cardiovascular, alcohol-related, or renal diseases
wereexcluded.Patients with a ,-antitrypsin deficiencywerealso excluded.
Control subjects did not show any sign of pulmonary disease, nor any
other disease. Patients and control subjects were matched for sex, age,
and smoking habit. All subjects were studied according to guidelines
of the Committee of Medical Ethics of the University Hospital Nijme-
gen and gave informed consent.
Static and dynamic lung function tests were performed with a wet
spirometer and with a closed-circuit helium-dilution method (Pulmo-
net III; Sensormedics, Bilthoven, the Netherlands). Diffusion capacity
(Kco) was measured with the single breath-holding carbon monoxide
method (Sensormedics 2450)and was corrected for actual hemoglobin.
Measurements were performed at least 12 h after smoking. Predicted
spirometric values werederived from the European Community for Steel
and Coal (E.C.S.C.) standards (22).
Arterial blood samples were taken after the patients had been sitting
for at least 15 min. Pao, and Paeo, were measured with a Corning Ph
127 blood gas analyzer (Corning Glass, Medfield, MA).
TABLE 2
PHYSIOLOGIC DATA OF PATIENTS WITH BRONCHIAL CARCINOMA,
WITH OR WITHOUT EMPHYSEMA
FEV1 FEV1
Patient Age (yr) TLC RV (% pred) (% pred) Kco Pa02 Pae02 Pack-
Code Sex (% pred) (% pred) before 5 after 5 (% pred) (kPa) (kPa) years
Patients with bronchial carcinoma and emphysema
15 64, F 113 119 44 47 53 8.1 5.6 40
67 60, M 94 114 61 58 61 10.6 5.3 35
72 75, M 136 120 64 68 78 10.6 5.1 10
44 58, M 116 157 64 67 68 8.3 4.6 20
71 66, M 112 105 42 39 46 8.0 5.5 40
45 70, M 96 100 75 74 71 8.9 5.4 50
58 77, M 109 95 80 78 52 10.3 5.4 15
18 78, M 132 89 70 71 54 9.5 4.9 20
Patients with bronchial carcinoma, without emphysema
21 58, M 79 65 76 76 120 13.5 5.2 20
65 68, M 102 106 75 75 86 7.0 5.48 20
37 72, M 96 86 104 104 123 9.8 4.8 10
41 96, M 93 103 75 75 90 7.7 5.0 25
3 68, M 85 78 71 75 89 10.6 4.5 30
8 81, M 103 81 110 115 83 11.2 4.9
56 64, M 66 65 47 50 93 9.2 5.6 40
39 63, M 98 110 71 75 104 8.2 5.3 30
For definition of abbreviations. seeTable 1.
* Nonsmoker.
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TABLE 3
PHYSIOLOGIC DATA OF PATIENTS WITH SARCOIDOSIS
Patient Age (yr) 8MI TLC RV FEV, Keo Pack- DC5
Code Sex (kg/m2) (% pred) (% pred) (% pred) (% pred) years (mg/day)
52 32, M 26.5 103 92 103 82 25
53 55, F 28.7 103 75 107 117 _t
54 41, F 23.2 77 72 66 101
55 38, F 24.7 90 66 83 119 5
56 25, F 21.5 116 122 110 76
57 32, F 30.9 85 76 91 146
58 31, M 24.2 77 58 90 127 3
59 60, F 37.3 87 5 109 131 10
510 61, F 22.6 82 82 80 125 5
511 33, M 20.9 78 79 53 59 16 10
512 41, M 24.5 93 83 97 125 5
513 59, F 27.1 93 71 111 125
514 28, F 25.9 80 64 79 96 15
515 43, M 27.4 90 73 86 106
516 32, F 19.8 80 111 91 95
Definition of abbreviations: DeS ~ oral corticosteroids. All other abbreviations, as defined in Table 1.
* Nonsmoker.
t No DeS.
Group 1:Patients with COPD and control subjects. Physiologic data
of all individual patients are shown in Table I. Patients were character-
ized by severe airways obstruction and (in most cases) hyperinflation,
and a reduced Keo. No improvement of FEV 1 was observed after inha-
lation of 400 ug salbutamo!. Patients were in a stable condition, with-
out exacerbations during the preceding 3 mo. All subjects used inhaled
!3,-sympathomimetics and/or anticholinergics. Fourteen patients (700/0)
used inhaled corticosteroids in a mean dosage of 630 ± 240 ug daily.
None used theophylline or oral corticosteroids. Lung function data and
body measures of control subjects are given in Table 4.
Group 2: Patients with bronchial carcinoma with and without em-
physema. Physiologic data of all individual patients are shown in Table
2. Patients were characterized by a recently detected and histologically
proven bronchial carcinoma (in all cases squamous cell carcinoma). Pa-
tients with bronchial carcinoma without emphysema had no radiographic
or histologic signs of emphysema, and total lung capacity and diffusion
capacity were within predicted mean ± 1.64 SD.
Group 3: Patients with sarcoidosis and control subjects. Physiologic
data of all individual patients are shown in Table 3. Patients had histo-
logically proven sarcoidosis stage 2 (mediastinal and/or hilar lymphad-
enopathy and radiographic signs of interstitial involvement). Six of 15
patients used oral corticosteroids in a dosage of 5 to 25 mg/d, whereas
the other patients did not receive any medication. Lung function data
and body measures of control subjects are given in Table 5.
Purification of Glycosaminoglycans from Urine
Urines werecollected and stored at -70 0 C. After thawing, 20-ml sam-
ples of urine were diluted with an equal volume of 7 M urea/lO mM
Tris-HCI pH 6.8 and applied to an ion-exchange column of 5 x 0.5 em
containing 1ml diethylaminoethyl (DEAE)-Sepharose Fast Flow (Phar-
macia, Uppsala, Sweden). After an initial wash with 3 ml 0.2 M NaCl/lO
mM Tris-HCI (pH 6.8), GAGs were eluted with 1 ml 2 M NaCl/lO mM
Tris-HCI (pH 6.8) followed by 3 milO mM Tris-HCI (pH 6.8). The recov-
TABLE 4
LUNG FUNCTION DATA AND BODY MEASURES OF
CONTROL SUBJECTS IN GROUP 1 (AGE, 51-85 YR)*
ery of the GAGs was monitored by adding 15,000dpm [3SSJGAGs (spe-
cific activity 104 dprn/ug GAG) to the urine. Salts were removed by eth-
anol precipitation of the GAGs. Five volumes of ethanol were added
(final ethanol concentration 83%) and GAGs were allowed to precipi-
tate for 16 h at -200 C. After centrifugation for 30 min at 10,000 g
(_10° C), the precipitated GAGs weredried and dissolvedin 2 ml deminer-
alized water. Recoverieswere between 88 and 100%.Twocyclesof freeze-
thawing ofurine did not influence the results. A third cycleoccasionally
gave erroneous data.
Quantification of Glycosaminoglycans
Sulfated GAGs were quantified according to the method of Farndale
and coworkers (23). This method is based on a metachromatic shift in
absorption maximum of 1,9-dimethylmethylene blue (DMMB) (Aldrich
Chemie Co., Bornem, Belgium).To 100IIIGAG sample, 2.5 ml ofDMMB
reagent was added and the absorbance at 525 nm wasmeasured immedi-
ately. The DMMB reagent contains 46 IlM DMMB (initially 46 umol
DMMB was dissolved in 5 ml 96% ethanol), 40 mM glycine, and 42
mM NaCl, adjusted to pH 3.0 with I M HC!. Chondroitin 4-sulfate
(Sigma, St. Louis, MO) was taken as a standard and included within
each series of assays.
Quantification of Total Heparan Sulfate
Three methods for the determination of HS were used. These methods
are based on different aspects of the HS structure. Bovine kidney HS
(Seikagaku, Tokyo, Japan) was used as a standard.
Method 1 is a modified version of the 1,9-dimethylmethylene blue
assay and is based on the backbone structure of heparan sulfate (24).
Addition of bovine serum albumin and adaptation of pH and salt con-
centration of the DMMB reagent results in a specific elimination of HS-
based absorbance. To 100 IIIGAG sample, 100 III3% bovine serum al-
bumin (BSA)(in demineralized water) and 2.4 ml of the modified DMMB
TABLE 5
LUNG FUNCTION DATA AND BODY MEASURES OF
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reagent was added. This reagent contains 48 11M DMMB (initially 48
umol DMMB was dissolved in 5 ml95OJo ethanol), 42 mM glycine, and
63 mM NaCl, adjusted to pH 2.75 with 1M HC!. After 30 min at 22° C
the absorbance was measured at 525 nm. By subtracting the value thus
obtained (representing other GAGs) from the total GAGs, the content
of HS was calculated (24).
Method 2, digestion of HS by heparitinase, is based on cleavage of
glycosidic linkages in HS involving glucuronic acid residues. To lyophy-
lized GAG samples, 25 111 heparitinase (Seikagaku, Tokyo, Japan) (0.01
IU/ml containing 0.05 M sodium acetate and 0.05 M calcium acetate
[pH 7.0]) was added. Incubation was for 16 h at 43° C. The remaining
GAGs were quantified using the 1,9-dimethylmethylene blue assay (see
quantification of GAGs). By subtracting this value from the total GAGs
the content of HS was determined.
Method 3, digestion with nitrous acid, is based on cleavage of glyco-
sidic linkages involving hexosamine residues in which the amino groups
are either N-sulfated or unsubstituted. Nitrous acid digests HS and hepa-
rin, but not other GAGs (25). Purified GAGs were treated for 90 min
at 22° C with nitrous acid prepared by mixing equal volumes of 5%
(wt/vol) NaNO. and 1.5 M HC!. The residual GAGs were quantified
using the 1,9-dimethylmethylene blue assay(seequantification of GAGs).
By subtracting this value from the the total GAG the content of HS and
heparin was obtained. The contribution of heparin is negligible.
Quantification of the HS JM403 Epitope
The HS JM403 epitope, defined by monoclonal antibody (mAb) JM403
(26,27),wasquantitated using an inhibition enzymeimmunoassay (Figure
1). In the wellsof polystyrene microtiter plates (Greiner GmbH, Frick-
enhausen, Germany; catalog number 655061), 100111 of ascites contain-
ing mAb JM403 (diluted 1:40,000 in Tris-bufferedsaline containing 0.1%
Tween20 and 1% [wt/vol] bovine serum albumin, pH 7.5 [TBST/BSA])
was mixed with 100 ul lyophylized GAG sample and incubated over-
night at 4° C. We transferred 100 111 of each well to a corresponding
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Figure 1. Standard curve for the inhibition immunoassay for the hepa-
ran sulfate epitope )M403. A volume of 100 111 containing various
amounts of bovine kidney HS was incubated for 16 h at 4° C with
50111 of) M403 antibody. Next, 100111 of this mixture was transferred
to a well previously coated with 1 I1g HS. After incubation for 2 h
at 22° C, the antibodies bound to the well were detected byaddi-
tion of alkaline phosphatase-conjugated secondary antibodies. Af-
ter addition of substrate the color developed was spectrophotometri-
cally measured at 405 nm. Data are mean ± SD (n = 3).
for 2 h. Free antibodies, i.e., antibodies not bound by HS of the sample,
were allowed in this wayto complex with the coated HS. After washing
thrice with TBST,bound antibodies weredetected by incubation for 1 h
at 22° C with 100 111 rabbit anti-mouse Ig (Dako, Glostrup, Denmark)
conjugated with alkaline phosphatase (diluted 1:2,000in TBST/BSA).
After washingagain, 100111 of substrate (1 mg/ml p-nitrophenylphosphate
in 1 M diethanolamine (pH 9.8) containing 50 mM MgCI,) was added,
and the reaction was allowed to proceed for 2 h at 22° C. The color
developedwasspectrophotometricallymeasured at 405nm. Bovinekidney
HS was taken as a standard within each series. One unit is defined as
the amount of epitope present on 1 I1g bovine kidney heparan sulfate.
Samples were analyzed in triple and at least three different twofold
dilutions were applied such that three points were in the steep part of
the standard curve. Samples of patients and control subjects were ana-
lyzed on the same microtiter plate. The intra- and interassay coefficients
of variation were 5.2 and 12.6%, respectively.
Other Procedures
Urinary creatinine was determined using the alkaline picrate method
(procedure number 555; Sigma, St. Louis, MO).
Statistical Analysis
Valuesare given as mean ± SEM, unless indicated otherwise. Intergroup
comparison was calculated using the Mann-Whitney test. Correlation
analysis was performed using Spearman's rank correlation test. P values
less than 0.05 were considered significant.
RESULTS
Pilot experiments showed that the urinary content of HS JM403
epitope and of HS on base of creatinine remained constant dur-
ing the day, and from day to day. This also holds for GAGs, which
is in agreement with data from the literature (28). There was no
correlation between age and urinary content of HS and GAG.
There was, however, a correlation between age and content of
HS JM403 epitope (r = 0.26, p < 0.03).
In patients with COPD the content of urinary GAGs was not
altered compared with controls (Figure 2, Table 6). The urinary
content of HS, measured by three different methods, was also
not changed (Figure 3, Table 6). The urinary content of the HS
JM403 epitope was significantly decreased in patients with COPD
(Figure 4, Table 6).
To examine the specificity of this finding, we studied two ad-
ditional groups of patients: patients with bronchial carcinoma
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Figure 2. Glycosaminoglycan content in the urine of individual con-
trol subjects and patients with COPD. Open squares: control; closed
squares: patient with COPD.
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TABLE 6
URINARY CONTENT OF GLYCOSAMINOGLYCANS,
HEPARAN SULFATE, AND HEPARAN SULFATE JM403 EPITOPE OF
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tope is basement membrane specific (26). In lung the propor-
tion of JM403 epitope per milligram of HS is quite high, e.g.,
in rat lung 35-fold higher than in kidney and heart (Van Den
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Figure 3. Heparan sulfate content in the urine of individual control
subjects and patients with COPD measured using (A) a modified 1,9-
dimethylmethylene blue assay; (8) nitrous acid digestion; (C) hepa-











urinary content of the HS JM403 epitope was significantly lower
in patients with bronchial carcinoma with emphysema compared
with patients with bronchial carcinoma without emphysema (Fig-
ure 5, Table 7). Urinary GAG and HS content were not different
(Table7). Patients with bronchial carcinoma without emphysema
had similar HS JM403 values as control subjects.
In urines of sarcoidosis patients no altered content of the HS
JM403 epitope was found (Figure 6, Table 8). Urinary GAG and
HS concentration were also not changed (Table 8).
DISCUSSION
In the urine of patients with COPD we found a decreased con-
tent of the HS JM403 epitope together with a normal content
of HS. The major group of patients studied (Group 1)was iden-
tified on a clinical basis, including lung function tests, and had
a strong reduction of predicted FEVr- Although we had no histo-
logic evidence, the presence of emphysema is likely in the lungs
of patients with COPD (29). In addition, the group of patients
with bronchial carcinoma with histologically proven emphysema
showed a reduced content of the HS JM403 epitope.
All values were normalized to the creatinine content, but
COPD patients often have a reduced concentration of creatinine
in the urine because of reduced muscle mass (29). Correcting for
this would result in a downward adjustment of the values for
COPD patients. This would make the difference between the HS
JM403/mg creatinine values of control subjects and COPD pa-
tients even greater. A decreased HS JM403 value as a result of
blocking of the epitope by a component present in the urine is
unlikely, since prior to analysis, urine samples were first diluted
with an equal volume of 7 M urea/IO mM Tris-HCI. Urea is a
chaotropic agent which disrupts noncovalent bonds. GAGs were
subsequently purified using ion-exchange chromatography.
The specificity of the decreased HS JM403 value in COPD
patients was confirmed by data of two additional groups of pa-
tients (patients with bronchial carcinoma with and without em-
physema, and patients with sarcoidosis). Because all but one pa-
tient in the group of bronchial carcinoma are smokers, a major
effect of smoking is not likely. Likewise, a major effect of medi-
cation is also unlikely because the group of patients with sar-
coidosis who receivedoral corticosteroids had no decrease of uri-
nary HS JM403 epitope. The content of HS determined with three
different assays, based on different aspects of the HS molecule,
showed no significant differences between patients and control
subjects. Differences in urinary GAG and HS content, however,
may be obscured by the relatively small contribution of GAG
and HS derived from the lung. The amount of lung-derived HS
JM403 epitope may, however, be quite substantial. Lung paren-
chyma is rich in basement membranes and the HS JM403 epi-
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Figure 4. Heparan sulfate jM403 epitope content in the urine of in-
dividual control subjects and patients with COPD. One unit is de-
fined as the amount of epitope present on 1 ~g bovine kidney hepa-
ran sulfate.Opensquares:control; closedsquares:patient with COPD.
The normal content of HS and the decreased content of the
HS JM403 epitope, suggest a structural alteration in or an al-
tered processing of the HS molecule in the lungs of emphysema-
tous patients. At present, we do not know the exact nature of
the epitope recognized by the JM403 antibody. Studies on chem-
ically and enzymatically modified HS indicate that the epitope
contains one or more N-unsubstituted glucosamine and n-glu-
curonic acid units, and is located in a region of the heparan sul-
fate chain composed of mixed N-sulfated and N-acetylated dis-
accharide units (30). The biologic significance of N-unsubstituted
glucosamines has recently been demonstrated in the binding of
HS to L-selectin (31). Blocking of the epitope in the glomerular
basement membrane by injection of JM403 antibody leads to
proteinuria in rats (27). Interestingly, microalbuminuria has re-
cently been described in a small group of patients with COPD
(32).
The etiology of pulmonary emphysema is not known. Con-
sidering that the development of (clinically evident) emphysema
is a process of several decades, the basic alteration may be quan-
titatively small in nature. The decreased content of a specific epi-
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Figure 5. Heparan sulfate jM403 epitope content in the urine of in-
dividual patients with bronchial carcinoma with and without emphy-
sema. Opensquares:patient without emphysema; closedsquares:pa-
tient with emphysema.
Figure 6. Heparan sulfate jM403 epitope content in the urine of in-
dividual control subjects and patients with sarcoidosis. Opensquares:
control; closed squares: patient with sarcoidosis.
urines of emphysema patients hints at a small, but significant
alteration. Alterations in the HS molecule would have conse-
quences for the protecting HS-proteoglycan barrier of the al-
veolus (14). In view of the functions of HS (antiprotease activ-
ity, binding and modulation of growth factors and cytokines,
involvement in the fibrillogenesis of collagen and elastin), this
could lead to a destabilization of the extracellular matrix, ulti-
mately resulting in emphysematous lesions. This concept is sup-
ported by the findings in rats that specific inhibition of proteogly-
can synthesis induces emphysematous lesions (33) and that HS
proteoglycans are very vulnerable toward elastase degradation
(34). In a genetic model for emphysema, the tight-skin mouse,
antibodies to HS have been detected (35).
TABLE 7
URINARY CONTENT OF GLYCOSAMINOGLYCANS, HEPARAN
SULFATE, AND HEPARAN SULFATE jM403 EPITOPE OF PATIENTS
WITH BRONCHIAL CARCINOMA WITH
AND WITHOUT EMPHYSEMA*
Patients without Patients with
Content Emphysema Emphysema
(per mg creatinine) (n = 8) (n = 7) Significance
Glycosaminoglycan, I1g 16.7 ± 2.4 16.5 ± 2.2 NS
Heparan sulfate
Modified DMMB assay, I1g 6.4 ± 0.7 6.6 ± 0.7 NS
Epitope JM403, U 2.4 ± 0.5 0.4 ± 0.1 p < 0.0005
NS= not significant.
• Values are mean ± SEM. Characteristics of patients are given in Table 2.
TABLE 8
URINARY CONTENT OF GLYCOSAMINOGLYCANS, HEPARAN
SULFATE, AND HEPARAN SULFATE jM403 EPITOPE OF CONTROL
SUBJECTS AND PATIENTS WITH SARCOIDOSIS
Content Controls Patients
(per mg creatinine) (n = 41) (n = 15) Significance
Glycosaminoglycan, I1g 14.3 ± 0.5 12.8 ± 0.9 NS
Heparan sulfate
Modified DMMB assay, I1g 4.3 ± 0.3 3.0 ± 1.0 NS
Epitope IM403, U 2.4 ± 0.4 1.7 ± 0.2 NS
NS =not significant.
• Values are mean ± SEM. Characteristics of control subjects are given in Table 5, of
patients in Table 3.
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In conclusion, urines from patients with COPD/emphysema
contain normal levels of GAGs and HS, but on the excreted HS
the e~pres.sion of a spe~ific epitope is decreased. Considering the
physiologic role of HS In alveoli, this alteration may be associated
with the pathogenesis of emphysema. Future research will focus
on structural analysis of heparan sulfate from the lung paren-
chyma of patients with emphysema and on the usefulness of the
HS JM403 epitope for early diagnosis of emphysema.
Acknowledgment The writers express their gratitude to Ronald Moers for ex-
cellent practical assistance.
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